Cadila Healthcare misbranded Saroglitazar, says US FDA

In a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading. It directed the company to cease violating the legal provisions in the US and respond before Jan. 6, 2017.